← Back to Home

Directly correcting the sickle cell mutation, nula-cel receives FDA Regenerative Medicine Advanced Therapy designation

Three patients no longer need transfusions and have experienced no vaso-occlusive events after treatment, giving nula-cel access to closer development discussions with the FDA. But the evidence underlying this regulatory milestone remains very early, and more complete data are needed to determine how long the benefits last and what safety trade-offs treatment entails.

By SURL BioNews

For patients with sickle cell disease, damage caused by abnormal red blood cells can continue to accumulate beyond episodes of pain. Correcting the stem cells that produce blood cells could offer a way to change the course of the disease at its source. Kamau Therapeutics announced on November 12 that its investigational therapy nula-cel had received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), providing closer regulatory consultation for this approach to directly repairing the disease-causing mutation.

The designation is based on preliminary results from the ongoing Phase 1/2 RESTORE trial. According to the company, all three patients who received the product made using an optimized manufacturing process no longer require transfusions and have experienced no vaso-occlusive events after treatment. Only two have been followed for more than six months; both had sickle hemoglobin levels below 20%, with normal adult hemoglobin making up most of their hemoglobin. These changes offer signs of efficacy, but observations in three patients are insufficient to estimate treatment outcomes in a broader patient population.

The strategy behind nula-cel involves collecting patients’ own hematopoietic stem cells and using homology-directed repair outside the body to change the disease-causing mutation in the β-globin gene back to the normal adult sequence, before infusing the cells back into the body. The therapy is designed to restore the production of normal adult hemoglobin. Whether a single treatment can provide lasting effects depends on whether the corrected stem cells can continue to survive, self-renew and maintain stable blood cell production.

The practical significance of RMAT designation is that it allows the development team to discuss trials and the evidence needed for review with the FDA earlier and more frequently. nula-cel has previously received Fast Track and Orphan Drug designations. Kamau said it will next request a multidisciplinary meeting to discuss plans for the data needed to support a marketing application and potential endpoints for accelerated approval. RMAT designation itself does not guarantee marketing approval, priority review or accelerated approval.

A same-day report from BioPharm International noted that RESTORE is an open-label trial without a control group, with planned enrollment of approximately 15 patients aged 12 to 40 with severe disease. Its primary purpose is to assess safety. The efficacy data drawing attention this time come from only three patients treated with the product made using the optimized process. Follow-up is also insufficient to establish whether the early improvements will persist, much less to determine superiority over other treatments.

Safety also needs to be considered alongside efficacy. The announcement of the designation did not provide complete safety results or the pretreatment conditioning regimen, and the relevant interim results have not yet been published in a peer-reviewed paper. The absence of vaso-occlusive events represents an encouraging change in disease manifestations, but it cannot replace an assessment of the entire treatment process, adverse reactions and long-term risks.

For nula-cel, the next test is to turn early signals from a small number of patients into reproducible, sustained clinical evidence. The company expects to release more interim efficacy data from RESTORE later this year. Results from additional patients, long-term blood cell production and complete safety records will determine whether this gene-correction strategy can advance to larger-scale validation.

References

  1. Kamau Therapeutics via GlobeNewswire
  2. BioPharm International